Modeling pulmonary fibrosis with bleomycin
MA Mouratis, V Aidinis - Current opinion in pulmonary medicine, 2011 - journals.lww.com
MA Mouratis, V Aidinis
Current opinion in pulmonary medicine, 2011•journals.lww.comDespite its disadvantages, the bleomycin animal model remains the best available
experimental tool for studying disease pathogenesis and testing of novel pharmaceutical
compounds. Two such compounds currently showing some promise in clinical trials have
emerged through the bleomycin model and preliminary results of basic research using this
model have shown that more candidate compounds may follow in the near future.
experimental tool for studying disease pathogenesis and testing of novel pharmaceutical
compounds. Two such compounds currently showing some promise in clinical trials have
emerged through the bleomycin model and preliminary results of basic research using this
model have shown that more candidate compounds may follow in the near future.
Summary
Despite its disadvantages, the bleomycin animal model remains the best available experimental tool for studying disease pathogenesis and testing of novel pharmaceutical compounds. Two such compounds currently showing some promise in clinical trials have emerged through the bleomycin model and preliminary results of basic research using this model have shown that more candidate compounds may follow in the near future.
Lippincott Williams & Wilkins